Table 4.

Univariate and Multivariate Predictors of Death Within 6 Months

Predictor	Univariate HR (95% CI), p-value	Multivariate HR (95% CI), p-value
Child’s C vs A	7.72 (4.40-13.47), <0.0001	6.12 (2.74-13.76), <0.0001
Child’s B vs A	1.99 (1.20-3.34), 0.0078	2.61 (1.36-4.80), 0.004
No Treatment vs TACE, RFA, or Sorafenib	3.55 (2.11-5.99), 0.0001	2.79 (1.60-4.88), 0.0003
AFP >1000 ng/ml	1.76 (1.19-2.61), 0.0049	2.47 (1.56-3.84), <0.0001
Female Gender	1.74 (1.13-2.70), 0.011	1.73 (1.03-2.90), 0.039
MELD (per point)	1.12 (1.08-1.15), <0.0001	1.07 (1.03-1.12), 0.002
Tumor Size (per cm)	1.04 (1.00-1.08), 0.04	1.05 (1.01-1.10), 0.015
BCLC Stage D vs A/B	9.60 (3.28-26.84), <0.0001	*
Arterial Hypovascularity	1.93 (1.31-2.82), 0.0008	1.33 (0.86-2.10), 0.21
Biliary Ductal Dilatation	1.90 (1.26-2.88), 0.0022	0.90 (0.53-1.52), 0.70

^*Due to colinearity, Child’s class and BCLC stage were not included in the same multivariate model; Child’s class was retained in the final model over BCLC stage because the majority of the patients had advanced BCLC stage C or D